JP5305554B2 - 鉄ニトロシル化ヘモグロビンの生成 - Google Patents

鉄ニトロシル化ヘモグロビンの生成 Download PDF

Info

Publication number
JP5305554B2
JP5305554B2 JP2004560325A JP2004560325A JP5305554B2 JP 5305554 B2 JP5305554 B2 JP 5305554B2 JP 2004560325 A JP2004560325 A JP 2004560325A JP 2004560325 A JP2004560325 A JP 2004560325A JP 5305554 B2 JP5305554 B2 JP 5305554B2
Authority
JP
Japan
Prior art keywords
hemoglobin
blood
nitrite
inorganic nitrite
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004560325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514643A (ja
JP2006514643A5 (https=
Inventor
ジョナサン エス． スタムラー，
デービッド ジェイ． シンゲル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2006514643A publication Critical patent/JP2006514643A/ja
Publication of JP2006514643A5 publication Critical patent/JP2006514643A5/ja
Application granted granted Critical
Publication of JP5305554B2 publication Critical patent/JP5305554B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2004560325A 2002-12-12 2003-12-10 鉄ニトロシル化ヘモグロビンの生成 Expired - Fee Related JP5305554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43261602P 2002-12-12 2002-12-12
US60/432,616 2002-12-12
PCT/US2003/037081 WO2004054433A2 (en) 2002-12-12 2003-12-10 Forming iron nitrosyl hemoglobin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010039447A Division JP2010120971A (ja) 2002-12-12 2010-02-24 鉄ニトロシル化ヘモグロビンの生成

Publications (3)

Publication Number Publication Date
JP2006514643A JP2006514643A (ja) 2006-05-11
JP2006514643A5 JP2006514643A5 (https=) 2006-12-14
JP5305554B2 true JP5305554B2 (ja) 2013-10-02

Family

ID=32595081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004560325A Expired - Fee Related JP5305554B2 (ja) 2002-12-12 2003-12-10 鉄ニトロシル化ヘモグロビンの生成
JP2010039447A Withdrawn JP2010120971A (ja) 2002-12-12 2010-02-24 鉄ニトロシル化ヘモグロビンの生成

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010039447A Withdrawn JP2010120971A (ja) 2002-12-12 2010-02-24 鉄ニトロシル化ヘモグロビンの生成

Country Status (6)

Country Link
US (1) US8075922B2 (https=)
EP (1) EP1575419B1 (https=)
JP (2) JP5305554B2 (https=)
AU (2) AU2003295697B2 (https=)
CA (1) CA2509817C (https=)
WO (1) WO2004054433A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294543T3 (es) 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
AU2006220548B2 (en) 2005-03-07 2011-04-21 Sangart, Inc. Composition and methods for delivering carbon monoxide (CO) and nitric ozide (NO) CO to tissue using heme proteins as carriers
CN1325518C (zh) * 2005-09-09 2007-07-11 李勇 人细胞膜抗原的保存方法及磁性粒子包被人细胞膜抗原
DE102007026071A1 (de) * 2007-05-24 2008-11-27 Seereal Technologies S.A. Richtungsgesteuerte Beleuchtungseinheit für ein autostereoskopisches Display
WO2009029836A2 (en) * 2007-08-31 2009-03-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes
WO2009038796A1 (en) 2007-09-20 2009-03-26 Wake Forest University Health Sciences Methods of treatment for hemolysis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US6291424B1 (en) 1991-11-14 2001-09-18 Brigham And Women's Hospital Nitrosated and nitrosylated heme proteins
WO1996030006A1 (en) * 1995-03-24 1996-10-03 Brigham And Women's Hospital Nitrosylated blood substitutes
US6153186A (en) 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
AT405135B (de) * 1997-01-17 1999-05-25 Immuno Ag Präparation umfassend thiolgruppen-hältige proteine
EP1015490B1 (en) 1997-02-06 2004-04-14 Duke University No-modified hemoglobins and uses therefor
US6087087A (en) 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
DE60043731D1 (de) * 1999-08-02 2010-03-11 Univ Duke Methode zur bestimmung der physiologischen wirkungen von hämoglobin
AU2003232019A1 (en) * 2002-05-29 2003-12-19 Duke University Measuring nitric oxide in blood gases and treatments based thereon

Also Published As

Publication number Publication date
AU2003295697A1 (en) 2004-07-09
JP2006514643A (ja) 2006-05-11
US20060252671A1 (en) 2006-11-09
WO2004054433A2 (en) 2004-07-01
WO2004054433A3 (en) 2005-09-09
JP2010120971A (ja) 2010-06-03
EP1575419A4 (en) 2009-11-11
CA2509817A1 (en) 2004-07-01
EP1575419B1 (en) 2015-05-27
AU2010201151B2 (en) 2012-12-13
AU2010201151A1 (en) 2010-04-15
US8075922B2 (en) 2011-12-13
AU2003295697A8 (en) 2004-07-09
CA2509817C (en) 2014-11-04
AU2003295697B2 (en) 2009-12-24
EP1575419A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
Belcher et al. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice
Standl et al. Hemoglobin-based oxygen carrier HBOC-201 provides higher and faster increase in oxygen tension in skeletal muscle of anemic dogs than do stored red blood cells
Sakai et al. Hemoglobin vesicles and red blood cells as carriers of carbon monoxide prior to oxygen for resuscitation after hemorrhagic shock in a rat model
JP2003515533A (ja) 副作用が減少されたヘモグロビン組成物
JP2010120971A (ja) 鉄ニトロシル化ヘモグロビンの生成
Alayash et al. Hemoglobin and free radicals: implications for the development of a safe blood substitute
Ketcham et al. Hemoglobin-based oxygen carriers: development and clinical potential
MX2008014648A (es) Metodos para tratar la anemia aguda por perdida de sangre con un sustituto de la sangre con hemoglobina reticulada.
JPH02115200A (ja) ヘモグロビン系血液代用物質およびその調製方法
US20050129747A1 (en) Use of one or more natural or modified oxygen carriers, devoid of plasma and cellular membrane constiuents, for externally treating open, in particular chronic wounds
ES2202535T3 (es) Hemoglobina provista de ligandos protectores de los sitios de union al oxigeno artificial para la aplicacion biologico-medica directa y procedimiento para su preparacion.
EP4101296B1 (en) Normothermic machine organ perfusion fluid and preparation method therefor
Levy The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss
Galiñanes et al. PEG-SOD and myocardial protection. Studies in the blood-and crystalloid-perfused rabbit and rat hearts.
EP3794943A1 (en) Composition for preserving biomaterial, method for preserving biomaterial, method for producing biomaterial, transplantation material and transplantation method
Asanuma et al. S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts
Scatena et al. O-raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier
Smani Hemospan: a hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia
Beutler et al. The effect of 2, 3-DPG on the sickling phenomenon
Rosen et al. Effect of hemoglobin solution on compensation to anemia in the erythrocyte-free primate
Standl Artificial oxygen carriers as red blood cell substitutes–perfluorocarbons and cell-free hemoglobin
Papassotiriou et al. Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators
JP2006514643A5 (https=)
RU1801499C (ru) Способ лечени гипоксических состо ний
Prempeh et al. Hemoglobin (Hemolink): History

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110511

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110609

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120501

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130625

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees